Alvotech

About Alvotech

Alvotech is a purpose-driven company specializing in the development and manufacturing of biosimilars to improve lives by expanding access to affordable biologic medicines. Their mission focuses on better access and better lives through a vertically integrated approach from cell line development to manufacturing.

Products & Services

Biosimilars:High-quality, cost-competitive biosimilars aimed at providing affordable biologic medicines to patients worldwide.

Pipeline (AVT06):Includes AVT06, a proposed biosimilar to Eylea (aflibercept), recommended for market approval by the European Medicines Agency.

Biosimilars

Biologic medicines

Specialties

Biosimilars Biologic Medicines Vertically Integrated Manufacturing Vertically integrated development and manufacturing Cell line development Fill and finish manufacturing

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering with concurrent Private Placement T: - FT: Public Offering with concurrent Private Placement	A: 165000000 MR: - FA: $165 million FAN: 165000000	D: 2026-06-18 FD: 2026-06-18	3 investors
2	RT: Public Offering and Private Placement T: - FT: Public Offering and Private Placement	A: 152000000 MR: - FA: $152 million FAN: 152000000	D: 2026-06-16 FD: 2026-06-16	-
3	RT: Public Offering with Concurrent Private Placement T: - FT: Public Offering with Concurrent Private Placement	A: 125000000 MR: - FA: $125 million FAN: 125000000	D: 2026-06-15 FD: 2026-06-15	-
4	RT: Term Loan T: - FT: Term Loan	A: 100000000 MR: - FA: USD 100 million FAN: 100000000	D: 2025-12-31 FD: 2025-12-31	1 investors
5	RT: Debt T: - FT: Debt	A: 1081000000 MR: - FA: US$1,081 million FAN: 1081000000	D: 2025-06-26 FD: 2025-06-26	1 investors
6	RT: Private Placement T: - FT: Private Placement	A: 7500000 MR: - FA: 7.5 million shares FAN: 7500000	D: 2025-06-11 FD: 2025-06-11	1 investors
7	RT: Private Placement T: - FT: Private Placement	A: 750000000 MR: - FA: SEK 750 million FAN: 750000000	D: 2025-06-04 FD: 2025-06-04	-
8	RT: Debt T: - FT: Debt	A: 965000000 MR: - FA: $965 million FAN: 965000000	D: 2024-07-11 FD: 2024-07-11	-
9	RT: Convertible Debt T: - FT: Convertible Debt	A: 220735780 MR: - FA: 220735780 FAN: 220735780	D: 2024-07-01 FD: 2024-07-01	-
10	RT: Directed Offering T: - FT: Directed Offering	A: 166000000 MR: - FA: approximately USD 166 million FAN: 166000000	D: 2024-02-26 FD: 2024-02-26	1 investors
11	RT: Convertible Bond Private Placement T: - FT: Convertible Bond Private Placement	A: 100000000 MR: - FA: $100 million FAN: 100000000	D: 2023-07-31 FD: 2023-07-31	1 investors
12	RT: Private Placement T: - FT: Private Placement	A: 137000000 MR: - FA: approximately $137 million FAN: 137000000	D: 2023-01-23 FD: 2023-01-23	-

Public Offering with concurrent Private Placement Latest

2026-06-18

$165.0M

3 investors (Pro only)

Public Offering and Private Placement 2026-06-16

$152.0M

Public Offering with Concurrent Private Placement 2026-06-15

$125.0M

View 11 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

L

Lisa Graver

Chief Executive Officer

T

Tanya Zharov

General Counsel

L

Linda Jónsdóttir

Chief Financial Officer

J

Joseph E. McClellan

Chief Operating Officer

A

Anthony M. Maffia III

Chief Quality and Regulatory Officer

B

Balaji Prasad

Chief Strategy Officer

View 11 more team members with Pro

Unlock Full Team Directory

Recent News

Alvotech Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised